Loading...
ESMO congress Lung Cancer 20162025-01-28T17:04:45+01:00

ESMO 2016 – Copenhagen

 

Lecture Board: Maximilian Hochmair, MD; Anders Mellemgaard, MD, PhD; Silvia Novello, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ESMO 2016

ESMO 2016 English

Full report (english)

ESMO 2016 Spanish

Full report (spanish)

ESMO 2016 Mandarin

Full report (mandarin)

EXPERT VIDEOS

All video interviews from ESMO 2016

Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.

Martin Reck discusses the management of immunotherapy related adverse events.

Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.

Anders Mellemgaard on anti-angiogenesis treatments

Of course, from a clinician’s point of view, therapeutic innovation is the more spectacular part of lung-cancer–related changes. Novel approaches address targets that are not confined to the tumour cell, which had been at the centre of treatment considerations for a long time.

Silvia Novello • MD • PhD, University of Turin, Italy
Go to Top